Ovarian Clear Cell Carcinoma in Cowden Syndrome

View More View Less
  • a Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, Oncogénétique Clinique, CHU Montpellier, Université de Montpellier, Montpellier; Unité d'Oncogénétique, Institut Bergonié, INSERM U1218, Université de Bordeaux, Bordeaux; Département d'Oncologie Médicale, Service de Gynécologie-Obstétrique, and Service d'Anatomopathologie, CHU Montpellier, Université de Montpellier, Montpellier; Unité d'Anatomie Pathologique, Institut Bergonié, INSERM U1218, Université de Bordeaux, Bordeaux; Service de Dermatologie, CHU Montpellier, Université de Montpellier, Montpellier; Service d'Oncogénétique, Hôpital Pellegrin, CHU de Bordeaux; Service d'Oncogénétique, Hôpital Charles Nicolle, CHU de Rouen; and Service de Génétique Médicale, CHU de Toulouse, Université de Médecine Toulouse III, Toulouse, France.
Restricted access

Cowden syndrome (CS) is an autosomal dominant mendelian disease related to germline pathogenic variants affecting the PTEN-gene. CS is characterized by macrocephaly, mucocutaneous lesions, and an increased risk of breast and thyroid cancers. Rare ovarian cancer cases (mostly embryonic tumors) associated with PTEN have been described in the literature, but no current CS guidelines are available for ovarian cancer risk management. We report on a woman diagnosed with ovarian clear cell carcinoma (OCCC) at 28 years of age. The patient displayed macrocephaly, trichilemmomas, oral papillomatosis, and acral keratosis. A family history of multiple cancer cases within the PTEN-related tumor spectrum was identified. In addition, PET scan and fine-needle biopsy results led to a diagnosis of thyroid follicular neoplasia. PTEN sequencing revealed that she carried a germline inherited pathogenic variant in exon 5 c.388C>T, p.(Arg130*) (NM_000314). Somatic mismatch repair immunohistochemistry analysis showed normal expression, and germline BRCA1/2 sequencing did not reveal pathogenic or likely pathogenic variants. An ovarian cell immunohistochemistry analysis reported total loss of PTEN expression, which strongly suggested the role of PTEN in the oncogenesis of this cancer. Hence, a total thyroid resection was performed instead of thyroid lobectomy and a risk-reducing bilateral mastectomy was discussed. Co-occurrence of this pathogenic germline mutation in PTEN in this patient, early development of OCCC at age 28 years, and total loss of PTEN expression in the tumor might support the involvement of PTEN in the carcinogenesis of her ovarian cancer. We describe a new ovarian cancer case with an atypical histologic type—clear cell carcinoma—in CS. This observation might be the first indication of the need to expand the PTEN-related tumor spectrum to incorporate OCCC. The CS diagnosis significantly changed the therapeutic outcome of this patient.

Correspondence: Carole Corsini, MD, Service D'oncogénétique, CHU Montpellier, Hôpital Arnaud de Villeneuve, 371 Avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France. Email: c-corsini@chu-montpellier.fr
  • 1.

    Prat J. FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol 2015;26:8789.

    • Search Google Scholar
    • Export Citation
  • 2.

    Lheureux S, Karakasis K, Harter P. Germline BRCA1/2 testing practices in ovarian cancer: current state and opportunities for new directions. Gynecol Oncol 2016;140:9094.

    • Search Google Scholar
    • Export Citation
  • 3.

    Bubien V, Bonnet F, Brouste V. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet 2013;50:255263.

  • 4.

    Daly MB, Pilarski R, Berry MP, NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 1.2018. Accessed June 28, 2018. To view the most recent version of these guidelines, visit NCCN.org.

    • Search Google Scholar
    • Export Citation
  • 5.

    Eng C. PTEN hamartoma tumor syndrome. In: Adam MP, Ardinger HH, Pagon RA, eds. GeneReviews. Seattle, WA: University of Washington; 1993–2018. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1488/. Accessed June 28, 2018.

    • Search Google Scholar
    • Export Citation
  • 6.

    Tan MH, Mester JL, Ngeow J. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012;18:400407.

  • 7.

    Ngeow J, Sesock K, Eng C. Clinical implications for germline PTEN spectrum disorders. Endocrinol Metab Clin North Am 2017;46:503517.

  • 8.

    Stewart SL, Harewood R, Matz M. Disparities in ovarian cancer survival in the United States (2001-2009): findings from the CONCORD-2 study. Cancer 2017;123(Suppl 24):51385159.

    • Search Google Scholar
    • Export Citation
  • 9.

    Karnezis AN, Cho KR, Gilks CB. The disparate origins of ovarian cancers: pathogenesis and prevention strategies. Nat Rev Cancer 2017;17:6574.

    • Search Google Scholar
    • Export Citation
  • 10.

    Seidman JD, Horkayne-Szakaly I, Haiba M. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2004;23:4144.

    • Search Google Scholar
    • Export Citation
  • 11.

    Fujiwara K, Shintani D, Nishikawa T. Clear-cell carcinoma of the ovary. Ann Oncol 2016;27(Suppl 1):i5052.

  • 12.

    Ramalingam P. Morphologic, immunophenotypic, and molecular features of epithelial ovarian cancer. Oncology 2016;30:166176.

  • 13.

    Kobayashi H, Kajiwara H, Kanayama S. Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary (review). Oncol Rep 2009;22:233240.

    • Search Google Scholar
    • Export Citation
  • 14.

    Gounaris I, Brenton JD. Molecular pathogenesis of ovarian clear cell carcinoma. Future Oncol 2015;11:13891405.

  • 15.

    Bubien V, Bonnet F, Brouste V. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet 2013;50:255263.

  • 16.

    Rau A, Flister MJ, Rui H, Auer PL. Exploring drivers of gene expression in The Cancer Genome Atlas. Bioinformatics 2019;35:6268.

  • 17.

    Helder-Woolderink JM, Blok EA, Vasen HF. Ovarian cancer in Lynch syndrome; a systematic review. Eur J Cancer 2016;55:6573.

  • 18.

    Chui MH, Ryan P, Radigan J. The histomorphology of Lynch syndrome–associated ovarian carcinomas. Am J Surg Pathol 2014;38:11731181.

  • 19.

    Risch HA, McLaughlin JR, Cole DE. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700710.

    • Search Google Scholar
    • Export Citation
  • 20.

    Murakami R, Matsumura N, Brown JB. Exome sequencing landscape analysis in ovarian clear cell carcinoma shed light on key chromosomal regions and mutation gene networks. Am J Pathol 2017;187:22462258.

    • Search Google Scholar
    • Export Citation
  • 21.

    Kuo KT, Mao TL, Jones S. Frequent activating mutations of PIK-3CA in ovarian clear cell carcinoma. Am J Pathol 2009;174:15971601.

  • 22.

    Ho CM, Lin MC, Huang SH. PTEN promoter methylation and LOH of 10q22–23 locus in PTEN expression of ovarian clear cell adenocarcinomas. Gynecol Oncol 2009;112:307313.

    • Search Google Scholar
    • Export Citation
  • 23.

    PTEN in Ovarian Cancer. My Cancer Genome website. Available at: https://www.mycancergenome.org/content/disease/ovarian-cancer/pten/. Accessed June 28, 2018.

    • Search Google Scholar
    • Export Citation
  • 24.

    Oda K, Ikeda Y, Kashiyama T. Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies. J Obstet Gynaecol Res 2016;42:757762.

    • Search Google Scholar
    • Export Citation
  • 25.

    Sato M, Kawana K, Adachi K. Targeting glutamine metabolism and the focal adhesion kinase additively inhibits the mammalian target of the rapamycin pathway in spheroid cancer stem-like properties of ovarian clear cell carcinoma in vitro. Int J Oncol 2017;50:14311438.

    • Search Google Scholar
    • Export Citation
  • 26.

    Pujol P, Lyonnet DS, Frebourg T. Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests. Breast Cancer Res Treat 2013;141:135144.

    • Search Google Scholar
    • Export Citation
  • 27.

    Moretta J, Berthet P, Bonadona V. [The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition.] Bull Cancer 2018;105:907917 [in French].

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 2926 2032 172
PDF Downloads 295 191 5
EPUB Downloads 0 0 0